Literature DB >> 35192139

Natural Killer Cells: the Missing Link in Effective Treatment for High-Grade Serous Ovarian Carcinoma.

Morgan Pugh-Toole1,2, Anna P Nicolela3, Sarah Nersesian2,4, Brendan M Leung1,2,5,6, Jeanette E Boudreau7,8,9.   

Abstract

OPINION STATEMENT: Ovarian cancer (OC), especially high-grade serous cancer (HGSC), is a highly heterogeneous malignancy with limited options for curative treatment and a high frequency of relapse. Interactions between OC and the immune system may permit immunoediting and immune escape, and current standard of care therapies can influence immune cell infiltration and function within the tumor microenvironment. Natural killer (NK) cells are involved in cancer immunosurveillance and immunoediting and can be activated by therapy, but deliberate approaches to maximize NK cell reactivity for treatment of HGSC are in their infancy. NK cells may be the ideal target for immunotherapy of HGSC. The diverse functions of NK cells, and their established roles in immunosurveillance, make them attractive candidates for more precise and effective HGSC treatment. NK cells' functional capabilities differ because of variation in receptor expression and genetics, with meaningful impacts on their anticancer activity. Studying HGSC:NK cell interactions will define the features that predict the best outcomes for patients with the disease, but the highly diverse nature of HGSC will likely require combination therapies or approaches to simultaneously target multiple, co-existing features of the tumor to avoid tumor escape and relapse. We expect that the ideal therapy will enable NK cell infiltration and activity, reverse immunosuppression within the tumor microenvironment, and enable effector functions against the diverse subpopulations that comprise HGSC.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Combination therapy; High-grade serous carcinoma; Immunotherapy; Natural killer cells; Ovarian cancer

Mesh:

Year:  2022        PMID: 35192139     DOI: 10.1007/s11864-021-00929-x

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  66 in total

1.  Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.

Authors:  Katherine C Fuh; Angeles A Secord; Kerri S Bevis; Warner Huh; Adam ElNaggar; Kevin Blansit; Rebecca Previs; Todd Tillmanns; Daniel S Kapp; John K Chan
Journal:  Gynecol Oncol       Date:  2015-07-02       Impact factor: 5.482

Review 2.  Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.

Authors:  Elizabeth K Lee; Ursula A Matulonis
Journal:  Expert Opin Emerg Drugs       Date:  2020-06-22       Impact factor: 4.191

3.  Ovarian cancer statistics, 2018.

Authors:  Lindsey A Torre; Britton Trabert; Carol E DeSantis; Kimberly D Miller; Goli Samimi; Carolyn D Runowicz; Mia M Gaudet; Ahmedin Jemal; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2018-05-29       Impact factor: 508.702

Review 4.  Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features.

Authors:  Jaime Prat
Journal:  Virchows Arch       Date:  2012-02-10       Impact factor: 4.064

5.  Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer.

Authors:  David R Kroeger; Katy Milne; Brad H Nelson
Journal:  Clin Cancer Res       Date:  2016-01-13       Impact factor: 12.531

Review 6.  The biology of ovarian cancer: new opportunities for translation.

Authors:  Robert C Bast; Bryan Hennessy; Gordon B Mills
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

Review 7.  The forefront of ovarian cancer therapy: update on PARP inhibitors.

Authors:  M R Mirza; R L Coleman; A González-Martín; K N Moore; N Colombo; I Ray-Coquard; S Pignata
Journal:  Ann Oncol       Date:  2020-06-20       Impact factor: 32.976

8.  Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer.

Authors:  Céline M Laumont; Maartje C A Wouters; Julian Smazynski; Nicole S Gierc; Elizabeth A Chavez; Lauren C Chong; Shelby Thornton; Katy Milne; John R Webb; Christian Steidl; Brad H Nelson
Journal:  Clin Cancer Res       Date:  2021-05-07       Impact factor: 12.531

Review 9.  Recent concepts of ovarian carcinogenesis: type I and type II.

Authors:  Masafumi Koshiyama; Noriomi Matsumura; Ikuo Konishi
Journal:  Biomed Res Int       Date:  2014-04-23       Impact factor: 3.411

10.  Construction of an Immune Cell Infiltration Score to Evaluate the Prognosis and Therapeutic Efficacy of Ovarian Cancer Patients.

Authors:  Jinhui Liu; Yichun Wang; Shuning Yuan; Junting Wei; Jianling Bai
Journal:  Front Immunol       Date:  2021-10-20       Impact factor: 7.561

View more
  1 in total

1.  Pan-cancer analysis of the angiotensin II receptor-associated protein as a prognostic and immunological gene predicting immunotherapy responses in pan-cancer.

Authors:  Kai Hong; Yingjue Zhang; Lingli Yao; Jiabo Zhang; Xianneng Sheng; Lihua Song; Yu Guo; Yangyang Guo
Journal:  Front Cell Dev Biol       Date:  2022-08-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.